Chlamydia (CT) and gonorrhea (NG) can have serious long-term consequences including pelvic inflammatory disease (PID), ectopic pregnancy and infertility.1 Accurate testing and treatment are critical to protecting sexual and reproductive health. Our CT/GC assay delivers reliable results from multiple specimen types, including self and clinician-collected vaginal swabs and first-catch male and female urine.
The most common curable STI
Trichomonas vaginalis (TV) is the most common curable STI in the United states.1 Over 3.7 million people in the United States have TV, which is a higher prevalence than chlamydia and gonorrhea infections combined.1 The CDC recommends testing women for TV infection if they are symptomatic or at increased risk of infection.2
Detect up to 100% of TV Infections
Our Trichomonas vaginalis assay is an rRNA-based NAAT that provides up to 100% sensitivity in detecting TV for both symptomatic and asymptomatic patients.3,4 This assay overcomes challenges associated with traditional, less sensitive methodologies because it can detect a fraction of one organism, whereas wet mount requires at least 10,000 motile organisms/mL to visualize.3,4
- CDC. CDC Fact Sheet: Incidence, Prevalence and Cost of Sexually Transmitted Infections in the United States. https://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf. February 2013.
- Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70(4):1-187.doi.org/10.15585/mmwr.rr7004a1.
- Aptima Trichomonas vaginalis Assay. US package insert 503684. Hologic, Inc., 2020.
- Garber GE. The laboratory diagnosis of Trichomonas vaginalis. Can J Infect Dis Med Microbiol. 2005; 16(1):35-38. doi.org/10.1155/2005/373920